1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo ...
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring ...
1. In patients with advanced, platinum-resistant ovarian cancer, combination therapy of a tyrosine kinase inhibitor, pazopanib, with paclitaxel significantly increased ...
Image: PD 1. Pazopanib and sunitinib showed similar efficacy in treating metastatic renal-cell carcinoma as a first-line therapy. 2. Quality-of-life ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
